Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Brave

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
European Urology|June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell CarcinomaDaniel Lee, Haley Gittleman, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateMichael Brave, Vicki Goodman, Edvardas Kaminskas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
European Urology|June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell CarcinomaDaniel Lee, Haley Gittleman, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateMichael Brave, Vicki Goodman, Edvardas Kaminskas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.
Pageof 2